Sam Brusco, Associate Editor06.20.24
Tandem Diabetes Care has named Jean-Claude “JC” Kyrillos as its new executive VP and chief operating officer (COO), effective June 21, 2024.
Kyrillos was previously in operating company president roles at Envista Holdings from February 2020 to June 2023, most recently president of the company’s Diagnostics and Digital Solutions. Before that, he was senior VP and GM at Qualcomm Life from May 2016 to February 2019.
Prior to Qualcomm, Kyrillos had leadership positions at ResMed from January 2008 to August 2011, most recently as president of ResMed Ventures and Initiatives. He also served as an independent board director of San Diego Blood Bank since January 2016 and as Chair from January 2020 to December 2022.
“I was drawn to Tandem's dedication to making a positive impact in the diabetes community, while addressing growing demand for smaller, more advanced insulin delivery technologies,” said Kyrillos. "I look forward to adding my experience to the talented team already in place and helping deliver on Tandem’s mission through the expansion of our global operations while delivering profitable growth.”
“JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multiple roles in large and small medical technology companies,” said John Sheridan, Tandem Diabetes’ president and CEO. “JC shares our strong commitment to helping improve lives, and I look forward to working together as we advance our pipeline to bring more solutions to people living with diabetes.”
Last month, the company announced the Tandem Mobi pump with Control-IQ is now compatible with both the Dexcom G7 and G6 continuous glucose monitoring (CGM) systems.
Kyrillos was previously in operating company president roles at Envista Holdings from February 2020 to June 2023, most recently president of the company’s Diagnostics and Digital Solutions. Before that, he was senior VP and GM at Qualcomm Life from May 2016 to February 2019.
Prior to Qualcomm, Kyrillos had leadership positions at ResMed from January 2008 to August 2011, most recently as president of ResMed Ventures and Initiatives. He also served as an independent board director of San Diego Blood Bank since January 2016 and as Chair from January 2020 to December 2022.
“I was drawn to Tandem's dedication to making a positive impact in the diabetes community, while addressing growing demand for smaller, more advanced insulin delivery technologies,” said Kyrillos. "I look forward to adding my experience to the talented team already in place and helping deliver on Tandem’s mission through the expansion of our global operations while delivering profitable growth.”
“JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multiple roles in large and small medical technology companies,” said John Sheridan, Tandem Diabetes’ president and CEO. “JC shares our strong commitment to helping improve lives, and I look forward to working together as we advance our pipeline to bring more solutions to people living with diabetes.”
Last month, the company announced the Tandem Mobi pump with Control-IQ is now compatible with both the Dexcom G7 and G6 continuous glucose monitoring (CGM) systems.